Corrigendum to “Rb selectively inhibits innate IFN-β production by enhancing deacetylation of IFN-β promoter through HDAC1 and HDAC8” [J. Autoimmun. 73C (2016) 42–53](S0896841116300737)(10.1016/j.jaut.2016.05.012);Rb selectively inhibits innate IFN-β production by enhancing deacetylation of IFN-β promoter through HDAC1 and HDAC8

Journal of Autoimmunity

Volumn 73, Issue , 2016, Pages 42-53

  Meng, Jun ^a   Liu, Xingguang ^b   Zhang, Peng ^b   Li, Dong ^c   Xu, Sheng ^b   Zhou, Qingqing ^b   Guo, Meng ^b   Huai, Wanwan ^a   Chen, Xiang ^b   Wang, Quanxing ^b   Li, Nan ^b   Cao, Xuetao ^a,b,d  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Histone deacetylase; IFN ; Inflammation; Innate immunity; Retinoblastoma protein

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1 INTERFERON; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 8; HISTONE H3; HISTONE H4; PROTEIN C JUN; RETINOBLASTOMA PROTEIN; HDAC1 PROTEIN, MOUSE; HDAC8 PROTEIN, MOUSE; HISTONE; HISTONE DEACETYLASE; INTERLEUKIN 6; INTERLEUKIN-6, MOUSE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEACETYLATION; DNA VIRUS INFECTION; ENHANCER REGION; EPIGENETICS; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; INFLUENZA VIRUS; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RNA VIRUS INFECTION; VIRAL CLEARANCE; ACETYLATION; ANIMAL; AUTOIMMUNE DISEASE; FEMALE; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; PROMOTER REGION; RAW 264.7 CELL LINE; RNA INTERFERENCE; VIRUS INFECTION;

ACETYLATION; ANIMALS; AUTOIMMUNE DISEASES; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; FEMALE; HEK293 CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-JUN; RAW 264.7 CELLS; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTORS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 84971634628     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2019.102380     Document Type: Erratum

References (38)

1. [1] Cooks, T., Pateras, I.S., Tarcic, O., Solomon, H., Schetter, A.J., Wilder, S., et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23 (2013), 634–646.
2. [2] Lowe, J., Shatz, M., Resnick, M., Menendez, D., Modulation of immune responses by the tumor suppressor p53. Biodiscovery, 8, 2013, 2.
3. [3] O'Neill, L.A., Golenbock, D., Bowie, A.G., The history of Toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 13 (2013), 453–460.
4. [4] Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11 (2010), 373–384.
5. [5] Barbalat, R., Ewald, S.E., Mouchess, M.L., Barton, G.M., Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29 (2011), 185–214.
6. [6] Honda, K., Taniguchi, T., IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6 (2006), 644–658.
7. [7] Goubau, D., Deddouche, S., Reis e Sousa, C., Cytosolic sensing of viruses. Immunity 38 (2013), 855–869.
8. [8] Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140 (2010), 805–820.
9. [9] Cao, X., Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat. Rev. Immunol. 16 (2015), 35–50.
10. [10] Wu, J., Chen, Z.J., Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32 (2014), 461–488.
11. [11] Chen, W., Han, C., Xie, B., Hu, X., Yu, Q., Shi, L., et al. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell 152 (2013), 467–478.
12. [12] Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446 (2007), 916–920.
13. [13] Smale, S.T., Selective transcription in response to an inflammatory stimulus. Cell 140 (2010), 833–844.
14. [14] Yang, P., An, H., Liu, X., Wen, M., Zheng, Y., Rui, Y., et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat. Immunol. 11 (2010), 487–494.
15. [15] Kim, H., Seed, B., The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3. Nat. Immunol. 11 (2010), 743–750.
16. [16] Dick, F.A., Rubin, S.M., Molecular mechanisms underlying RB protein function. Nat. Rev. Mol. Cell. Biol. 14 (2013), 297–306.
17. [17] Garfin, P.M., Min, D., Bryson, J.L., Serwold, T., Edris, B., Blackburn, C.C., et al. Inactivation of the RB family prevents thymus involution and promotes thymic function by direct control of Foxn1 expression. J. Exp. Med. 210 (2013), 1087–1097.
18. [18] Bellacchio, E., Paggi, M.G., Understanding the targeting of the RB family proteins by viral oncoproteins to defeat their oncogenic machinery. J. Cell. Physiol. 228 (2013), 285–291.
19. [19] Browne, E.P., Wing, B., Coleman, D., Shenk, T., Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J. Virol. 75 (2001), 12319–12330.
20. [20] Brown, J.N., Kohler, J.J., Coberley, C.R., Sleasman, J.W., Goodenow, M.M., HIV-1 activates macrophages independent of Toll-like receptors. PLoS One, 3, 2008 e3664.
21. [21] Koziel, J., Maciag-Gudowska, A., Mikolajczyk, T., Bzowska, M., Sturdevant, D.E., Whitney, A.R., et al. Phagocytosis of Staphylococcus aureus by macrophages exerts cytoprotective effects manifested by the upregulation of antiapoptotic factors. PLoS One, 4, 2009 e5210.
22. [22] Yarilina, A., Park-Min, K.H., Antoniv, T., Hu, X., Ivashkiv, L.B., TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 9 (2008), 378–387.
23. [23] Subrata, L.S., Bizzintino, J., Mamessier, E., Bosco, A., McKenna, K.L., Wikstrom, M.E., et al. Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J. Immunol. 183 (2009), 2793–2800.
24. [24] Han, M.H., Lundgren, D.H., Jaiswal, S., Chao, M., Graham, K.L., Garris, C.S., et al. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J. Exp. Med. 209 (2012), 1325–1334.
25. [25] Liu, X., Zhan, Z., Li, D., Xu, L., Ma, F., Zhang, P., et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat. Immunol. 12 (2011), 416–424.
26. [26] Miller, M.S., Rialdi, A., Ho, J.S., Tilove, M., Martinez-Gil, L., Moshkina, N.P., et al. Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis. Nat. Immunol. 16 (2015), 485–494.
27. [27] Boesten, L.S., Zadelaar, A.S., van Nieuwkoop, A., Hu, L., Jonkers, J., van de Water, B., et al. Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice. FASEB J. 20 (2006), 953–955.
28. [28] Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., Forster, I., Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic. Res. 8 (1999), 265–277.
29. [29] Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414.
30. [30] Honda, K., Takaoka, A., Taniguchi, T., Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 25 (2006), 349–360.
31. [31] Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug. Discov. 13 (2014), 673–691.
32. [32] Braganca, J., Genin, P., Bandu, M.T., Darracq, N., Vignal, M., Casse, C., et al. Synergism between multiple virus-induced factor-binding elements involved in the differential expression of interferon A genes. J. Biol. Chem. 272 (1997), 22154–22162.
33. [33] Arnosti, D.N., Kulkarni, M.M., Transcriptional enhancers: intelligent enhanceosomes or flexible billboards?. J. Cell. Biochem. 94 (2005), 890–898.
34. [34] Panne, D., Maniatis, T., Harrison, S.C., An atomic model of the interferon-beta enhanceosome. Cell 129 (2007), 1111–1123.
35. [35] Shakespear, M.R., Halili, M.A., Irvine, K.M., Fairlie, D.P., Sweet, M.J., Histone deacetylases as regulators of inflammation and immunity. Trends. Immunol. 32 (2011), 335–343.
36. [36] Hutcheson, J., Bourgo, R.J., Balaji, U., Ertel, A., Witkiewicz, A.K., Knudsen, E.S., Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma. Hepatology 60 (2014), 1231–1240.
37. [37] Zheng, S.J., Lamhamedi-Cherradi, S.E., Wang, P., Xu, L., Chen, Y.H., Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54 (2005), 1423–1428.
38. [38] Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14 (2014), 36–49.